Tissue microRNA-21 expression predicted recurrence and poor survival in patients with colorectal cancer – a meta-analysis
Authors Chen Z, Liu H, Jin W, Ding Z, Zheng S, Yu Y
Received 8 January 2016
Accepted for publication 1 March 2016
Published 4 May 2016 Volume 2016:9 Pages 2615—2624
Checked for plagiarism Yes
Review by Single-blind
Peer reviewers approved by Dr Colin Mak
Peer reviewer comments 3
Editor who approved publication: Dr Jianmin Xu
Zexin Chen,1 Hui Liu,2 Wen Jin,2 Zheyuan Ding,2 Shuangshuang Zheng,2 Yunxian Yu2
1Department of Clinical Epidemiology and Biostatistics, The Second Affiliated Hospital, School of Medicine, Zhejiang University, 2Department of Epidemiology & Health Statistics, School of Public Health, School of Medicine, Zhejiang University, Hangzhou, People’s Republic of China
Objective: MicroRNA-21 (miR-21) has been shown to play an important role in cancer prognosis. We performed a meta-analysis to evaluate the prognostic effect of miR-21 from tissues and serum on survival of the patients with colorectal cancer (CRC).
Methods: Relevant studies were identified by searching PubMed, Embase, and Cochrane Library. Pooled hazard ratios (HRs) with 95% confidence intervals (CIs) of total and subgroup analyses, for overall survival (OS) and disease-free survival (DFS), were calculated to investigate the association between miR-21 expression and CRC prognosis.
Results: Our analysis included eleven studies (3,669 subjects). In addition, four studies explored the association between miR-21 and DFS, and ten studies focused on the prognostic value of miR-21 for OS. Our results indicated that increased miR-21 expression of tissues predicted both poor DFS and OS in patients with CRC (DFS: HR =1.59, 95% CI =1.20–2.10; OS: HR =1.53, 95% CI =1.23–1.90). Consistent results were observed among colon cancer and quantitative real-time polymerase chain reaction subgroups.
Conclusion: Meta-analysis indicated that miR-21 predicted recurrence and poor survival in patients with CRC. miR-21 may be more suitable to predict cancer prognosis in colon cancer patients.
Keywords: miR-21, prognostic value, colorectal cancer
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]